Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/BCMA
bispecific chimeric antigen receptors (CARs) T cell therapy for relapsed and refractory
multiple myeloma.